A 2-es típusú diabetesben szenvedök antidiabetics terápiája az akarbóz alkalmazásának helye

Translated title of the contribution: Antidiabetic therapy of patients with type 2 diabetes - The place of administration of acarbose

Research output: Contribution to journalArticle

Abstract

Administration of the alpha-glucosidase enzyme inhibitor acarbose leads to a prolonged absorption of carbohydrates, which has a smoothing effect on blood glucose excursions, and results in a more even daily blood glucose profile. The glucose lowering effect is mainly due to the reduction of postprandial blood glucose levels. Non-glycaemic effects of acarbose, including those on blood pressure, lipids and the coagulation system are also clearly beneficial. According to the available data, the preparation also reduces cardiovascular risk. If used as a monotherapy, acarbose does not cause hypoglycaemia. Flatulence and diaorrhea represent the main side effects. From a professional point of view, acarbose should be given if postprandial blood glucose excursions exceed 2.2 mmol/l.

Original languageHungarian
Pages (from-to)439-442
Number of pages4
JournalLege Artis Medicinae
Volume21
Issue number6-7
Publication statusPublished - Jun 2011

Fingerprint

Acarbose
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Blood Glucose
Flatulence
Enzyme Inhibitors
Therapeutics
Hypoglycemia
Carbohydrates
Blood Pressure
Lipids
Glucose

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A 2-es típusú diabetesben szenvedök antidiabetics terápiája az akarbóz alkalmazásának helye. / Kempler, P.

In: Lege Artis Medicinae, Vol. 21, No. 6-7, 06.2011, p. 439-442.

Research output: Contribution to journalArticle

@article{ee985517394a448aacd4de6f882128d4,
title = "A 2-es t{\'i}pus{\'u} diabetesben szenved{\"o}k antidiabetics ter{\'a}pi{\'a}ja az akarb{\'o}z alkalmaz{\'a}s{\'a}nak helye",
abstract = "Administration of the alpha-glucosidase enzyme inhibitor acarbose leads to a prolonged absorption of carbohydrates, which has a smoothing effect on blood glucose excursions, and results in a more even daily blood glucose profile. The glucose lowering effect is mainly due to the reduction of postprandial blood glucose levels. Non-glycaemic effects of acarbose, including those on blood pressure, lipids and the coagulation system are also clearly beneficial. According to the available data, the preparation also reduces cardiovascular risk. If used as a monotherapy, acarbose does not cause hypoglycaemia. Flatulence and diaorrhea represent the main side effects. From a professional point of view, acarbose should be given if postprandial blood glucose excursions exceed 2.2 mmol/l.",
keywords = "Acarbose, Alpha-glucosidase inhibition, Cardiovascular risk, Postprandial hyperglycaemia, Type 2 diabetes mellitus",
author = "P. Kempler",
year = "2011",
month = "6",
language = "Hungarian",
volume = "21",
pages = "439--442",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "6-7",

}

TY - JOUR

T1 - A 2-es típusú diabetesben szenvedök antidiabetics terápiája az akarbóz alkalmazásának helye

AU - Kempler, P.

PY - 2011/6

Y1 - 2011/6

N2 - Administration of the alpha-glucosidase enzyme inhibitor acarbose leads to a prolonged absorption of carbohydrates, which has a smoothing effect on blood glucose excursions, and results in a more even daily blood glucose profile. The glucose lowering effect is mainly due to the reduction of postprandial blood glucose levels. Non-glycaemic effects of acarbose, including those on blood pressure, lipids and the coagulation system are also clearly beneficial. According to the available data, the preparation also reduces cardiovascular risk. If used as a monotherapy, acarbose does not cause hypoglycaemia. Flatulence and diaorrhea represent the main side effects. From a professional point of view, acarbose should be given if postprandial blood glucose excursions exceed 2.2 mmol/l.

AB - Administration of the alpha-glucosidase enzyme inhibitor acarbose leads to a prolonged absorption of carbohydrates, which has a smoothing effect on blood glucose excursions, and results in a more even daily blood glucose profile. The glucose lowering effect is mainly due to the reduction of postprandial blood glucose levels. Non-glycaemic effects of acarbose, including those on blood pressure, lipids and the coagulation system are also clearly beneficial. According to the available data, the preparation also reduces cardiovascular risk. If used as a monotherapy, acarbose does not cause hypoglycaemia. Flatulence and diaorrhea represent the main side effects. From a professional point of view, acarbose should be given if postprandial blood glucose excursions exceed 2.2 mmol/l.

KW - Acarbose

KW - Alpha-glucosidase inhibition

KW - Cardiovascular risk

KW - Postprandial hyperglycaemia

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=79960765369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960765369&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:79960765369

VL - 21

SP - 439

EP - 442

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 6-7

ER -